• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Weight loss leading to reduction in clozapine levels and symptomatic worsening.

作者信息

Kumar Akash Prasanna, Song Sang Ik, Hahn Margaret, Zipursky Robert, Remington Gary, Agarwal Sri Mahavir

机构信息

From the Centre for Addiction and Mental Health (CAMH) (Prasanna Kumar, Song, Hahn, Zipursky, Remington, Agarwal); Department of Psychiatry (Prasanna Kumar, Song, Hahn, Zipursky, Remington, Agarwal) and Institute of Medical Science (Hahn, Zipursky, Remington, Agarwal), and Banting and Best Diabetes Centre (BBDC) (Hahn, Agarwal), and Department of Pharmacology, University of Toronto, Toronto, Ont. (Hahn); Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Hahn).

出版信息

J Psychiatry Neurosci. 2025 Aug 14;50(4):E275-E276. doi: 10.1503/jpn.250076. Print 2025 Jul-Aug.

DOI:10.1503/jpn.250076
PMID:40813136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12364440/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10f5/12364440/43ede71228d6/50-4-e275f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10f5/12364440/43ede71228d6/50-4-e275f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10f5/12364440/43ede71228d6/50-4-e275f1.jpg

相似文献

1
Weight loss leading to reduction in clozapine levels and symptomatic worsening.体重减轻导致氯氮平水平降低及症状恶化。
J Psychiatry Neurosci. 2025 Aug 14;50(4):E275-E276. doi: 10.1503/jpn.250076. Print 2025 Jul-Aug.
2
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.氯氮平联合不同抗精神病药物治疗难治性精神分裂症。
Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD006324. doi: 10.1002/14651858.CD006324.pub3.
3
Obesity Associated With Symptomatic Remission in Clozapine-Treated Individuals With Treatment-Resistant Schizophrenia.肥胖与氯氮平治疗的难治性精神分裂症患者的症状缓解相关。
J Clin Psychopharmacol. 2025;45(5):484-487. doi: 10.1097/JCP.0000000000002048. Epub 2025 Aug 11.
4
Risperidone versus other atypical antipsychotics for schizophrenia.利培酮与其他非典型抗精神病药物治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2011 Jan 19;2011(1):CD006626. doi: 10.1002/14651858.CD006626.pub2.
5
Treatment of clozapine-associated weight gain: a systematic review.氯氮平所致体重增加的治疗：一项系统评价
Eur J Clin Pharmacol. 2015 Apr;71(4):389-401. doi: 10.1007/s00228-015-1807-1. Epub 2015 Jan 28.
6
The Impact of Metformin on Weight and Waist Circumference in Patients Treated With Clozapine: A One-Year Retrospective Cohort Study.氯氮平治疗患者中二甲双胍对体重和腰围的影响：一项为期一年的回顾性队列研究。
Acta Psychiatr Scand. 2025 Mar 11;151(6):719-30. doi: 10.1111/acps.13796.
7
Clozapine versus other atypical antipsychotics for schizophrenia.氯氮平与其他非典型抗精神病药物治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2010 Nov 10(11):CD006633. doi: 10.1002/14651858.CD006633.pub2.
8
Sulpiride augmentation for schizophrenia.舒必利增效治疗精神分裂症。
Cochrane Database Syst Rev. 2010 Jan 20(1):CD008125. doi: 10.1002/14651858.CD008125.pub2.
9
Clozapine dose for schizophrenia.用于治疗精神分裂症的氯氮平剂量。
Cochrane Database Syst Rev. 2017 Jun 14;6(6):CD009555. doi: 10.1002/14651858.CD009555.pub2.
10
Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia.肠道微生物群与精神分裂症治疗抵抗的关联。
JAMA Psychiatry. 2024 Mar 1;81(3):292-302. doi: 10.1001/jamapsychiatry.2023.5371.

本文引用的文献

1
Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis.氯氮平与第二代抗精神病药物治疗难治性精神分裂症的疗效比较：一项系统评价和个体患者数据荟萃分析。
Lancet Psychiatry. 2025 Apr;12(4):254-265. doi: 10.1016/S2215-0366(25)00001-X. Epub 2025 Feb 26.
2
Semaglutide in Psychiatry-Opportunities and Challenges.司美格鲁肽在精神病学中的机遇与挑战。
JAMA Psychiatry. 2024 Oct 1;81(10):955-956. doi: 10.1001/jamapsychiatry.2024.2412.
3
Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review.
氯氮平治疗精神障碍的疗效和安全性：系统定量荟萃评价。
Transl Psychiatry. 2021 Sep 22;11(1):487. doi: 10.1038/s41398-021-01613-2.
4
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies.治疗成人精神分裂症的氯氮平的药物监测：挑战与策略的综述。
Expert Opin Drug Metab Toxicol. 2021 Oct;17(10):1211-1221. doi: 10.1080/17425255.2021.1974400. Epub 2021 Sep 6.
5
The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial.通过对双盲试验数据应用统计模型来确定体重变化对血浆总氯氮平浓度的影响。
J Clin Psychopharmacol. 2018 Oct;38(5):442-446. doi: 10.1097/JCP.0000000000000926.
6
Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.司美格鲁肽是一种每周注射一次的人胰高血糖素样肽-1（GLP-1）类似物，不会降低复方口服避孕药炔雌醇/左炔诺孕酮的生物利用度。
J Clin Pharmacol. 2015 May;55(5):497-504. doi: 10.1002/jcph.443. Epub 2015 Jan 14.
7
Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.血浆氯氮平、去甲氯氮平和氯氮平：去甲氯氮平比值与处方剂量及其他因素的关系：1993-2007 年治疗药物监测服务的数据。
Ther Drug Monit. 2010 Aug;32(4):438-47. doi: 10.1097/FTD.0b013e3181dad1fb.
8
Metabolic side effects of antipsychotic medication.抗精神病药物的代谢副作用。
Int J Clin Pract. 2007 Aug;61(8):1356-70. doi: 10.1111/j.1742-1241.2007.01416.x.